The world’s first approved bispecific ADC has landed in China. This piece walks through why it carries two guidance systems, how target pairs are chosen, how far the pipeline has come — and the four open questions still ahead.
Read on WeChat →
The antibody finds the way; the oligonucleotide does the work. With Novartis committing around USD 12 billion to AOCs, how can genetic medicines reach muscle, brain and heart beyond the liver? A concise guide to the principle, targets, tissue delivery and open challenges.
Read on WeChat →
ADCs deliver cytotoxic payloads to kill tumour cells; PROTACs degrade disease-causing proteins. Combining the two yields degrader-antibody conjugates (DACs). With BMS’s USD 180 million acquisition and Roche’s USD 1 billion-plus collaboration, multinational companies are backing this modality with real capital.
Read on WeChat →Articles open on the official WeChat account of HKIG Immune Technology.
Tell us about your target and timeline — we will come back with a scope and a quotation.
Request a Quote →
